A Phase 1, Randomized, Double-blind, Placebo-controlled Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of ALN-6222 in Adult Participants With Obesity
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 1
SUMMARY
This is a first in human, randomized, double-blind (DB), placebo-controlled, single ascending dose (SAD), Phase 1 study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and efficacy of ALN-6222 administered subcutaneously (SC) in adult participants with obesity.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 65
Healthy Volunteers: f
View:
• Is an adult patient with a body mass index ≥30 kg/m\^2 to \<40 kg/m\^2
• Has a hemoglobin A1c \<6.5%
Locations
Other Locations
Canada
Clinical Trial Site
RECRUITING
Mount Royal
Contact Information
Primary
Alnylam Clinical Trial Information Line
clinicaltrials@alnylam.com
1-877-ALNYLAM
Backup
Alnylam Clinical Trial Information Line
clinicaltrials@alnylam.com
1-877-256-9526
Time Frame
Start Date: 2026-06-04
Estimated Completion Date: 2027-12-14
Participants
Target number of participants: 88
Treatments
Experimental: ALN-6222
Participants will be administered a single dose of ALN-6222.
Placebo_comparator: Placebo
Participants will be administered a single dose of placebo.
Related Therapeutic Areas
Sponsors
Leads: Alnylam Pharmaceuticals